NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTI stock has increased by 18.1% and is now trading at $1.37. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics.

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteostasis Therapeutics.

Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. View Proteostasis Therapeutics' earnings history.

5 Wall Street analysts have issued 12 month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $5.20 in the next year. This suggests a possible upside of 279.6% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics.

News articles about PTI stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news about Proteostasis Therapeutics.

Proteostasis Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 3,080,000 shares, an increase of 10.0% from the May 31st total of 2,800,000 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 2.8 days. Currently, 7.3% of the company's shares are sold short. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include OrganiGram (OGI), ProQR Therapeutics (PRQR), Menlo Therapeutics (MNLO), IDEAYA Biosciences (IDYA), Bicycle Therapeutics (BCYC), AMAG Pharmaceuticals (AMAG), Spero Therapeutics (SPRO), Concert Pharmaceuticals (CNCE), Verastem (VSTM), Verrica Pharmaceuticals (VRCA), IVERIC bio (ISEE), Northwest Biotherapeutics (NWBO), MediciNova (MNOV), Agile Therapeutics (AGRX) and CymaBay Therapeutics (CBAY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Micron Technology (MU), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL) and Syndax Pharmaceuticals (SNDX).

(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.37.

Proteostasis Therapeutics has a market capitalization of $71.45 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

The official website for Proteostasis Therapeutics is www.proteostasis.com.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]